Imaging Modalities for Defining Unresectable Liver Involvement

Evidence Supporting MRI Superiority

The American College of Radiology recommends MRI with hepatobiliary contrast agents for defining unresectability, as it demonstrates superior sensitivity (90-100%) compared to CT (70-76%) for detecting liver metastases, directly impacting surgical decision-making and patient outcomes 1
MRI achieves 90-100% sensitivity for liver metastases, compared to 70-76% for 64-detector row CT, particularly in patients with liver metastases but no lung involvement 1
In colorectal cancer staging, MRI demonstrates sensitivity of 81.9% with specificity of 93.2%, compared to CT's sensitivity of 73% and specificity of 96.5% 2, 3

MRI demonstrates significantly better performance in detecting liver metastases in patients with fatty liver disease and following neoadjuvant chemotherapy, directly affecting resectability assessment 4
Hepatobiliary MRI is associated with lower rates of intrahepatic recurrence (48% vs 65%, P=0.04) and fewer repeat hepatectomies (13% vs 25%, P=0.03) in patients who underwent pre-chemotherapy and pre-surgical evaluations 4

High-quality MDCT with multiphase imaging can achieve detection rates of 85-91% for liver metastases, narrowing the gap with MRI, but is less effective in fatty liver or post-chemotherapy patients 2, 4
CT maintains a high negative predictive value of 90% and low false-positive rate of 3.9%, making it reliable when optimally performed, but should not be relied upon for definitive characterization of liver lesions 2, 4

The primary recommendation is to use MRI with hepatobiliary contrast agents as the primary modality for defining liver-only metastatic disease and assessing resectability, due to its superior sensitivity and specificity 1, 4
If MRI is contraindicated or unavailable, optimized multiphase CT with MDCT technique can be used, but with recognition of the 10-20% reduction in sensitivity for small lesions 2, 4

Accurate detection of all liver metastases determines surgical resectability, and complete resection of liver metastases improves 5-year survival from <1% to potentially curative outcomes, highlighting the importance of choosing the optimal imaging modality 2, 3
The choice of imaging modality directly affects mortality and quality of life, with MRI-associated improvements in intrahepatic recurrence rates (48% vs 65%) representing a substantial survival benefit 4